TRANSCRIPT

Q1 2025 — Prepared remarks

Q1 2025PDF · 13 pages218 KB
1
Philip Morris International Inc.
2025 First-Quarter Conference Call
April 23, 2025
JAMES BUSHNELL
(SLIDE 1.)
Welcome. Thank you for joining us. Earlier today, we issued a press release containing
detailed information on our 2025 first-quarter results. The press release is available
on our website at www.pmi.com.
(SLIDE 2.)
A glossary of terms, including the definition for smoke-free products as well as
adjustments, other calculations and reconciliations to the most directly comparable
U.S. GAAP measures for non-GAAP financial measures cited in this presentation are
available in Exhibit 99.2 to the company's Form 8-K dated April 23, 2025, and on our
Investor Relations website.
(SLIDE 3.)
Today’s remarks contain forward-looking statements and projections of future results.
I direct your attention to the Forward-Looking and Cautionary Statements disclosure
in today’s presentation and press release for a review of the various factors that could
cause actual results to differ materially from projections or forward-looking statements.
I’m joined today by Emmanuel Babeau, Chief Financial Officer.
Over to you, Emmanuel.

-- 1 of 13 --

2
EMMANUEL BABEAU
(SLIDE 4.)
Thank you, James, and welcome everyone.
In Q1, we delivered a very strong start to the year, with all key elements of the business
contributing strongly to deliver double-digit increases in organic net revenue, operating
income, and adjusted diluted EPS in both constant currency and dollar terms.
Our smoke-free business performed exceptionally well across all areas, with shipment
volumes up +14.4% year-on-year, organic net revenue growth of +20%, and
outstanding organic gross profit growth of +33% as all 3 smoke-free categories
expanded gross margins. This was especially fueled by the rapid growth of ZYN and
the continued volume momentum, operating leverage and scale benefits of IQOS. Our
smoke-free business now accounts for 44% of total gross profit, as we continue to
deploy our multicategory strategy across markets and broaden our growth
opportunities.
IQOS delivered close to +10% HTU adjusted IMS growth with continued strong
performance both in Japan and Europe, despite the annualization impact of the EU
characterizing flavor ban. We expect double-digit growth for the rest of the year.
ZYN once again delivered strong growth in the U.S., with shipments increasing by an
impressive +53% to reach 202 million cans, exceeding our initial expectations, as
demand remained strong and production capacity increased ahead of schedule in the
latter part of March, enabling some initial replenishment of trade inventories.
International nicotine pouch can volumes also grew by +53%, or by +182% excluding
the Nordics, demonstrating the global dynamism of this emerging category.
In e-vapor, VEEV Q1 performance was impressive, demonstrating its increasing
contribution within our multicategory offering. Shipments more than doubled year-on-
year and gross margins further expanded, driven by strong pod growth in Europe as
we increased our distribution and commercial activities.
Within combustibles, overall volume growth coupled with strong pricing and ongoing
cost initiatives drove a robust performance, despite notably negative geographic mix
from increased volumes in lower-margin markets.
Overall, the very strong and increasingly profitable underlying growth of our smoke-
free business was coupled with very solid combustible results and the added benefit
of favorable shipment timing. This allowed us to deliver +16% organic OI growth and

-- 2 of 13 --

3
+250 basis points of expansion in adjusted OI margins to reach 40.7%, and resulted
in strong double-digit adjusted diluted EPS growth in both currency-neutral and dollar
terms, despite currency headwinds.
While it is early in the year and there are a number of uncertainties in the global
economic outlook, we remain confident that we will achieve another year of superior
growth. As such, we now forecast double-digit adjusted diluted EPS growth, at
prevailing exchange rates.
(SLIDE 5.)
Turning to the headline numbers, we delivered volume growth of +3.9%, reflecting the
very strong dynamism of our smoke-free business. Combined with strong pricing and
despite unfavorable combustible mix, we delivered double-digit organic net revenue
growth of +10.2%, reaching $9.3 billion in total.
There was also a technical impact from the change in commercial model for the
Indonesia below-tier one cigarette segment, where we now act as a handling agent.
This results in lower net revenues and COGS but has no meaningful impact on gross
profit or OI. Excluding this effect, which will notably affect the first 3 quarters of the
year, organic net revenues grew by around +12%.
And as I mentioned, our smoke-free business was the primary driver behind our
organic adjusted OI growth of +16.0%, or +12.8% in dollar terms.
Q1 adjusted diluted EPS grew by +17.3% in constant currency, and by +12.7% in
dollar terms to $1.69. This includes a 7 cent unfavorable currency variance, notably
due to non-recurring transactional losses in the quarter linked to currency volatility.
This stronger than expected performance was primarily driven by the top-line and
gross margin results of our smoke-free business. Excellent ZYN performance was
further enhanced by the great work of our manufacturing team in accelerating capacity
initiatives. Strong IQOS HTU shipment growth includes a robust performance in
Europe and around 1 billion units in favorable shipment timing, which we expect to
reverse in H2. This was complemented by the resilience of our combustible business.
(SLIDE 6.)
Looking at category performance in more detail, our smoke-free business grew net
revenues by +20.4%, and gross profit by +33.1%. This led to an impressive +670 basis
points of organic gross margin expansion to surpass 70%, more than 5 points above
the gross margin of combustibles at the current category and geographic mix of SFPs.

-- 3 of 13 --

4
As I mentioned, this reflects an acceleration in gross margin expansion for all 3 smoke-
free categories, notably combined with the positive mix impact of ZYN’s accretive unit
economics, and pricing on both HTUs and ZYN. Very strong IQOS gross margin
expansion reflects the powerful growth and scale effects of this large and growing
business, manufacturing productivities and a comparison benefit from higher device
shipments in the prior year, when ILUMA i was launched in Japan.
On an organic basis, combustible net revenues and gross profit grew by +3.8% and
+5.3% respectively. While pricing was strong and volumes were positive, there was a
notably negative geographic mix this quarter due to growth in markets such as Turkey
and Egypt, in addition to the technical impact from Indonesia. We expect both pricing
and negative geographic mix to moderate over the rest of the year and target
combustible gross margin expansion organically and in dollar terms. As expected,
input cost headwinds eased compared to recent years, and based on current
assumptions we expect this to further improve in 2026.
(SLIDE 7.)
Taking a closer look at our volumes, shipment growth of +3.9% was primarily driven
by our smoke-free business, with all categories contributing positively, and placing us
on track for a fifth consecutive year of total volume growth.
Smoke-free volumes grew by +14.4%, above our full-year target range of +12% to
+14%, reflecting very positive contributions from IQOS, ZYN and VEEV. In addition to
the growth of these 3 brands, which I covered earlier, I would also note that our oral
smoke-free business includes U.S. moist snuff and Scandinavian snus, which declined
modestly in the quarter. Despite this, Oral SFP shipment growth accelerated versus
the prior quarter to +27%.
Cigarette volumes were positive for the fourth consecutive quarter, as we grew share
in a modestly declining industry, with continued growth in markets where smoke-free
products are not permitted, such as Turkey and India.
(SLIDE 8.)
You have heard us talk recently about our multicategory strategy for smoke-free
products, as we leverage on the strength of the IQOS brand and commercial
infrastructure in international markets to accelerate incremental growth from ZYN and
VEEV. This is evidenced by our strong SFP results in Q1, with visible accretion across
regions and markets.

-- 4 of 13 --

5
We have 46 markets with multiple smoke-free offerings, including 16 with all 3 PMI
categories on offer. The execution of this 3-pronged strategy is generating positive
results in markets such as the Czech Republic, Romania, Switzerland and our Global
Travel Retail business, in addition to promising starts in the UK and Italy. It is also
helping to bolster our position as the global smoke-free champion.
(SLIDE 9.)
Double-digit Q1 organic net revenue growth was again driven by all 3 key elements of
our structural growth model – namely volumes, pricing and smoke-free mix. Pricing
contributed +6.0 points, reflecting over +8% combustible pricing, and around +3% for
smoke-free excluding devices. The positive mix impact of the shift to smoke-free
products, including U.S. smoke-free mix, drove a further positive contribution of +3.1
points.
Overall, combustible geographic mix & other factors had an unfavorable impact of 2.7
points. This was more negative than in prior quarters, reflecting the technical Indonesia
impact and combustible market mix dynamics I explained earlier.
Currency had a negative impact of 3.9 points, with a further 0.5 points from
acquisitions and divestitures, which includes the divestment of Vectura.
(SLIDE 10.)
Turning now to gross margins, we delivered very strong expansion of +340 basis
points on an organic basis, and +360 basis points including currency, acquisitions and
divestitures. This comprised +180 basis points from pricing, more than offsetting an
80 basis point unfavorable impact from cost inflation net of productivities and other
cost items. Smoke-free growth delivered an excellent +230 basis points, with a flat
contribution from combustibles excluding pricing but including the Indonesia impact.
This excellent gross margin performance supported strong adjusted OI margin
expansion of +250 basis points, or +200 basis points organically after accounting for
the currency mix of our costs, the divestiture of Vectura and other scope effects.
This impressive margin expansion was delivered despite a 140 basis point impact of
higher SG&A costs driven by continued investment in our smoke-free growth, including
U.S. investments, a low cost comparison in the prior year and the impact of 2025
investment phasing. As we continue to invest in top-line growth, we target organic
SG&A growth broadly in line with net revenue growth for the year.

-- 5 of 13 --

6
We continue to drive manufacturing and back-office efficiencies, and delivered over
$180 million in gross cost savings in Q1 across both COGS and SG&A. After more
than $750m of savings in 2024, this places us nicely on track to achieve our $2 billion
target over 2024-26.
(SLIDE 11.)
Focusing now on our IQOS business. As expected, calendar effects and EU flavor ban
annualization impacted Q1 adjusted IMS, however the delivery of +9.4% growth
despite these factors marks continued strong underlying momentum.
We expect double-digit progress in the balance of the year, in line with our target of
+10 to +12% growth. Supporting this are commercial initiatives around brand-building
and continuous innovation on devices and consumables, as we progressively roll out
ILUMA i and new consumable variants of TEREA, LEVIA and DELIA. Over the longer
term, we have a rich IQOS innovation pipeline to further enhance the breadth and
quality of the user experience with this iconic brand. As disclosed in our latest
Integrated Report, over 99% of our 2024 adjusted R&D spend was on smoke-free
products, consistent with the last 4 years, as we continue to drive consumer-centered
product development.
(SLIDE 12.)
Turning to Europe, where we are building on the strength of our IQOS business to
create an integrated multicategory portfolio to accelerate consumer switching and
value creation. Total shipments of our flagship smoke-free brands advanced by
+17.5% in Q1, with an increasing contribution from both ZYN and VEEV. IQOS HTU
shipments grew more than 15%, including a positive comparison impact from the prior
year.
Our investment in brand-building initiatives are exemplified by the recent partnership
with renowned Italian designer Seletti at Milan Design week, as part of the IQOS
Curious X campaign.
For IQOS, Q1 HTU adjusted IMS grew by +7.4%, as we further accelerated our share
of cigarettes and HTUs to a record 11.4%. Many markets in the region grew adjusted
IMS by double-digits, including high-teens growth or more in Spain, Germany, Bulgaria
and Greece. This dynamism more than compensated for flavor ban annualization
which, as flagged last quarter, was especially pronounced in Q1 and most notably in
Italy. I am particularly pleased to report that sequential market share in Italy is trending
well, with a record high of 18.4% for Q1 and progressive increases through the quarter.

-- 6 of 13 --

7
Overall, regional Q1 adjusted IMS growth was in line with our expectations, and we
expect another robust quarter in Q2 followed by an acceleration in the second half.
Our experience of the flavor ban impact remains unchanged, with a broadly consistent
pattern of recovery across markets following implementation. We continue to expect
an impact of around 1 billion units in 2025, primarily due to annualization with only
Hungary and Slovakia implementing the ban so far this year. The most notable
remaining market is Poland where the clean-shelf date will be in early-2026.
We also continue to roll out new and improved variants of our tobacco-free
consumable LEVIA, which is driving promising results. This is well-illustrated by
Hungary, where LEVIA reached a double-digit share of PMI HTUs less than 3 months
from launch.
(SLIDE 13.)
Our fundamental progress in the region is highlighted by the consistent growth in key
city offtake shares. This also includes Hungary where Budapest share reached almost
42%, over 4 points higher than Tokyo. Impressively, 24 of the 34 markets where IQOS
is present in Europe have crossed the 10% key city share mark, with 6 above 30%.
Notable call-outs across the Region include London, Vienna, Zurich, Lisbon and
Athens.
The regulatory landscape is an important determinant of smoke-free progress, and we
are encouraged by recent positive developments in a number of markets which
recognize the role of Tobacco Harm Reduction in policy measures. This includes
Greece which introduced dedicated legislation supporting science-based claims on
smoke-free products, and Hungary where factual and science-based communications
to consumers on smoke-free products is allowed, versus a total advertising ban for
combustibles. In Ukraine, an excise tax differential on HTUs versus cigarettes was re-
introduced following a period of equal treatment.
(SLIDE 14.)
In Japan, we delivered HTU adjusted IMS growth of +9.3%, effectively marking the
10th quarter of double-digit growth after accounting for the leap year. HTU adjusted
share increased by 3 percentage points year-on-year and +1.6 points sequentially to
reach 32.2%, further highlighting the dynamism of the innovative IQOS brand and
product portfolio in this key market. IQOS HTUs captured more than three-quarters of
category growth in Q1, and combined with our cigarette business, PMI is now the
market leader by volumes, of which approximately 75% are HTUs.

-- 7 of 13 --

8
The overall smoke-free category continues to progress, reaching almost 48% on a
national offtake basis in March, with 13 cities and 8 prefectures now crossing the 50%
threshold.
(SLIDE 15.)
Globally, we continue to see very strong IQOS performance as illustrated by key city
offtake shares. Highlights include impressive year-on-year growth in the capitals of
Indonesia and Mexico to surpass 5% share, robust progress in the Middle East & North
Africa, and strong growth in Belgrade to 17.7% share despite increased competitive
activity. IQOS reached a new high in South Korea, with a 14.1% share in Seoul
supported by the launch of ILUMA i in a highly competitive market.
Offtake share performance in Cairo continues to be optically impacted by the growth
of the combustible market, where competitor supply has normalized.
Also worth highlighting is the excellent growth of our Global Travel Retail business,
which is a leading space for our multicategory offering. We recorded strong HTU
growth across all regions to reach share of over 18% in airports where IQOS is
present.
In the U.S., as planned, we commenced direct sales of IQOS 3 devices and HTUs in
Austin, Texas at the end of March, following targeted engagement with legal-age
nicotine consumers over recent months. While intentionally small-scale, we have
received strong interest with further IQOS 3 pilots planned in the coming months as
we prepare for the at-scale launch of IQOS ILUMA. As a reminder, we are not
assuming any significant HTU volumes from the U.S. in our full-year forecast.
(SLIDE 16.)
Switching to ZYN, which continues to resonate strongly with adult nicotine users as a
superior product with premium brand equity, and deliver excellent results.
Continued strong demand and increased production capacity enabled shipment
volume growth of +53% to reach over 200 million cans for the quarter. This +70 million
year-on-year increase is impressive, though we should note the prior year first quarter
featured notable depletion of retailer and distributor stock levels and therefore a sell-
out volume higher than shipments, and this quarter included the beginning of a
replenishment.
As we continue to expand production at our Owensboro plant, we accelerated one
planned step in this process to the latter part of March. This enabled increased

-- 8 of 13 --

9
shipments at quarter-end, and a pull-forward of initial distributor restocking. With very
limited flow-through of these additional shipments to retail in the quarter, this did not
yet have a meaningful impact on in-store availability. We target full normalization of
the supply situation in Q3 this year.
ZYN continues to perform very robustly at retail given the circumstances, with strong
double-digit offtake growth. According to Nielsen, Q1 offtake volumes grew by around
+15% year-on-year, with category value share remaining strong at over 70% despite
heavy competitor discounting. While Nielsen data is based on only a small sample of
stores, it also shows our offtake volume share has been held back by availability and
declined by 1.5 points sequentially to 61.5%. We already observe our share on MSA
data, which measures shipments from distributors to retail, recover to almost 66% in
March on the limited flow-through I just mentioned.
With category offtake growing at around +30 to 35% while the leading brand is supply-
constrained, we expect ZYN offtake to gradually accelerate in the coming months as
in-store availability improves and we reactivate commercial and marketing initiatives.
We remain excited about the growth prospects of this dynamic category, and its
potential to switch legal-age consumers from cigarettes and other traditional forms of
tobacco. ZYN remains the only nicotine pouch product authorized by the FDA, and
this includes all variants in both 3mg and 6mg strengths currently commercialized in
the U.S. As outlined at CAGNY, there is a large addressable market in the millions of
legal-age nicotine users in the U.S. and we plan to engage more actively beyond our
existing consumer base to other legal-age nicotine users.
Indeed, with strong latent demand and capacity expansion ahead of target, we now
raise our shipment forecast to 800 to 840 million cans for the year.
With the outstanding efforts of our team on the ground, we continue to work on
increasing capacity in our Kentucky facility. Construction of our second U.S.
manufacturing site in Colorado is well underway, with production due to commence in
early 2026. We remain, as we have been since entering the U.S., committed to
investing in U.S. manufacturing. The substantial investments we have made in the U.S
are expected to continue to result in significant job creation and economic contribution
to the country.
(SLIDE 17.)
Outside the U.S. we continue to roll-out ZYN, leveraging our presence with IQOS and
VEEV to drive awareness and trial with legal-age nicotine users. The total international
nicotine pouch category is nascent in almost all geographies and stands at around half

-- 9 of 13 --

10
the size of the U.S. in volume terms. We are now in 38 markets globally following Q1
launches in the UAE and Colombia, and ultimately see all addressable markets as
meaningful opportunities given the unique characteristics of the category.
Within the +53% growth of our international pouch can volumes, shipments almost
trebled outside of the Nordics, including promising momentum in European markets
such as Austria, Switzerland and the UK where we commenced a national key account
roll-out. In emerging markets, strong progress continues in Pakistan, Mexico and
South Africa. PMI Global Travel Retail is a notable standout, as it also increases global
visibility and awareness of ZYN within our multicategory offering.
(SLIDE 18.)
Finally, closing our smoke-free performance with e-vapor. VEEV plays an increasingly
important role within our multicategory universe, with growing volumes and gross
margins. Shipment volumes doubled year-on-year to 0.6 billion on an equivalent unit
basis, driven by very good performance in Europe, where the pod segment continued
to grow strongly, partially at the expense of disposables given increased bans and
restrictions for this format. We observe increasing VEEV ONE adoption rates and low
abandonment across key markets, which is testament to the quality and presentation
of this premium product to legal-age consumers.
(SLIDE 19.)
Turning to combustibles. Our business performed robustly in Q1 with organic net
revenue growth of +3.8%, or closer to +7% excluding the Indonesia technical impact.
This was driven by strong pricing of +8.3%, with notable contributions from Turkey,
Poland and Germany. With less favorable timing dynamics in H2, we continue to
expect full year combustible pricing of +5 to +6%.
The cigarette industry declined by 1.3% in Q1, due to growth in geographies where
SFPs are nascent or not present, more than offset by accelerated cigarette declines
elsewhere. Where SFPs are not permitted, such as in Turkey or India, we expect this
divergence to continue, supported in some cases by demographic trends.
Nonetheless, we continue to expect a low-single digit cigarette industry decline for the
year.
Category share was strong, growing 0.4 points in Q1, partly due to positive market
mix. Both Marlboro and our global brands portfolio reached all-time first quarter highs.
We continue to target broadly stable category share over time, with our main priorities
being maximizing value and supporting the growth of smoke-free products.

-- 10 of 13 --

11
Most importantly, combustible organic gross profit continued to grow robustly at +5.3%
following the recovery of 2024.
(SLIDE 20.)
This brings me to our outlook for 2025.
We delivered a very strong Q1, including better-than-expected margins, and we
remain confident we will achieve another year of superior growth. As such, we are
reconfirming the currency-neutral growth outlook we provided in February, despite a
backdrop of increased uncertainty in the global macro-economic environment. As a
global company with broadly diversified production and a worldwide supplier network,
including an established U.S. manufacturing base, we believe we are well-positioned
to mitigate potential supply chain challenges. While the situation is volatile, we do not
currently anticipate a material impact on our business from recently introduced or
discussed tariffs.
We expect a continuation of strong momentum from our smoke-free business,
including the benefits of further multicategory deployment. As I explained we are
raising our forecast for U.S. ZYN shipments to 800 to 840 million cans. This further
supports our forecast of +12-14% SFP shipment growth which incorporates
unchanged strong growth assumptions for IQOS.
We also continue to expect total PMI organic net revenue growth in the range of +6%
to +8%, organic OI growth of +10.5% to +12.5% and currency-neutral adjusted diluted
EPS growth of +10.5% to +12.5%.
As announced in this morning’s press release, we are raising our 2025 adjusted diluted
EPS forecast to $7.36 to $7.49. This now reflects +12% to +14% growth in dollar terms
and includes a favorable estimated currency impact of 10 cents at prevailing exchange
rates. This reflects recent strength in the Euro, Japanese Yen and Russian Ruble,
partly offset by a stronger Swiss Franc.
For Q2, we assume HTU shipment volumes of 37.5 to 38.5 billion, with another strong
quarter of HTU adjusted IMS growth of around +10%. For U.S. ZYN we expect
shipments to be at a similar level to Q1, as trade restocking continues and offtake
gradually accelerates. We forecast adjusted diluted EPS of $1.80 to $1.85, including
a favorable currency variance of 6 cents, at prevailing rates. We expect a strong H1
overall, with organic net revenue growth around the high end of our target range for
the full year, and organic OI growth slightly above.

-- 11 of 13 --

12
With regard to our balance sheet, deleveraging remains a key priority, and we continue
to target further reduction in 2025, placing us on track for our target ratio of around
2.0x by the end of 2026.
(SLIDE 21.)
We believe our growth profile is best-in-class within large-cap Consumer Goods, as
shown by our 3 year CAGR targets which we are well on track to meet or exceed.
Adjusted diluted EPS growth in dollar terms is a key priority and, as demonstrated in
2024, we are committed to taking pro-active steps to manage potential currency
volatility, including through our hedging activities.
(SLIDE 22.)
Behind the delivery of our growth lie the enormous efforts we have made to transform
our business over the last 10 years, and the continued drive towards our ambition to
become substantially smoke-free.
This quarter coincides with the publication of the 6th edition of our annual Integrated
Report, which provides a comprehensive view of our company’s performance across
both financial and non-financial dimensions. Highlights include the important efforts
and actions we are taking with regards to youth access prevention, as well as the
progress we have made on our operational efficiency, strengthening our resilience,
driving innovation, and ultimately future-proofing our business.
As explained in the report, our approach to sustainability is fundamentally business-
driven, with the objective of both sustaining and enhancing the growth of our smoke-
free transformation to drive continued value creation. I would encourage anyone with
an interest in how and why we are transforming to read it.
(SLIDE 23.)
I will now conclude today’s presentation with some key messages.
Following an excellent start to the year, we are on track for another year of strong
performance in 2025. While no company is immune to macro-economic volatility, we
believe we are well positioned to navigate external dynamics.
We have three powerful growth drivers, with pricing power and positive smoke-free
category mix on top of volume growth, where we target our fifth consecutive year of
expansion led by IQOS, ZYN & VEEV. As we continue to invest strongly behind our

-- 12 of 13 --

13
smoke-free brands, these drivers are also profit-accretive, and combined with our
proactive measures on pricing and cost we have great confidence in sustainable
adjusted diluted EPS growth in both currency-neutral and dollar terms.
Finally, we remain a highly cash-generative business with an unwavering commitment
to our progressive dividend policy. We look forward to further rewarding our
shareholders as our transformation delivers sustainable growth.
(SLIDE 24.)
Thank you. We are now happy to answer your questions.
JAMES BUSHNELL
(SLIDE 25.)
That concludes our call today. Thank you for joining us. If you have any follow-up
questions, please contact the Investor Relations team. Thank you again and have a
nice day.

-- 13 of 13 --